Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Cells and Tissue01:30

Bone Cells and Tissue

8.4K
Bones contain a relatively small number of cells entrenched in a matrix of organic and inorganic components. Although bone cells compose only a small amount of the bone volume, they are crucial to its function. Four types of cells are found within the bone tissue— osteoblasts, osteocytes, osteogenic cells, and osteoclasts.
Osteoblasts and Osteocytes
The osteoblast is the bone cell responsible for forming new bone tissue. It is found in the growing portions of bone, including the...
8.4K
Hormones and Bone Tissue01:17

Hormones and Bone Tissue

3.8K
The endocrine system produces and secretes hormones, which interact with the skeletal system. These hormones control bone growth, maintain bone once it is formed, and remodel it.
Hormones That Influence Osteoblasts and/or Maintain the Matrix
Several hormones are necessary for controlling bone growth and maintaining the bone matrix. The pituitary gland secretes growth hormone (GH), which, as its name implies, controls bone growth. This happens in several ways: first, it triggers chondrocyte...
3.8K
Bone as Supporting Connective Tissue01:23

Bone as Supporting Connective Tissue

6.9K
Bone tissue forms the internal skeleton of vertebrate animals, providing structure to the body.
Bone Matrix
Bone, or osseous tissue, is a connective tissue that has a large amount of two different types of matrix material. The organic matrix is similar to the matrix material found in other connective tissues, including some amount of collagen and elastic fibers. This gives strength and flexibility to the tissue. The inorganic matrix consists of mineral salts— mostly calcium salts—...
6.9K
Growth of Cartilage and Bone Tissue01:27

Growth of Cartilage and Bone Tissue

4.3K
Chondrocytes form a temporary cartilaginous model by dividing and secreting a thick gel-like extracellular matrix. Once the chondrocytes undergo programmed cell death, osteoblasts enter the site of the cartilaginous model. The process of replacing the temporary cartilaginous model with bone in an ordered manner is called endochondral ossification. In endochondral ossification, not all of the cartilage is replaced by bone tissue. Some cartilage that performs a protective and supportive function...
4.3K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.7K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.7K
Rous Sarcoma Virus (RSV) and Cancer01:03

Rous Sarcoma Virus (RSV) and Cancer

6.4K
Rous Sarcoma virus or RSV was discovered by F. Peyton Rous in the year 1911 as a filterable transmissible agent that could cause tumors in chickens. He won a Nobel Prize for this discovery in 1966. His experiments clearly demonstrated that some cancers could be caused by infectious agents and led to the discovery of many more cancer-causing viruses in animals as well as humans.
RSV is a retrovirus that contains two copies of a plus-strand  RNA genome. Its genome consists of four main open...
6.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

MiT fusions, TSC1-TSC2 divergence, and stem-like programs reveal distinct origins and vulnerabilities in PEComa.

Nature communications·2026
Same author

A pooled analysis of phase 2 clinical trials in advanced chordoma.

European journal of cancer (Oxford, England : 1990)·2026
Same author

Final report of the SIOP-CNS-GCT II protocol for germinoma-omitting radiotherapy boost is safe in localized disease in complete remission after chemotherapy.

Neuro-oncology·2026
Same author

Non-coding (nc) RNAs and breast cancer treatment related sequelae: Current evidence and perspectives.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Dose-dependent cerebrovascular impact of pediatric brain radiotherapy revealed by advanced MRI: the AVARTHEC study.

Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology·2026
Same author

Natural history and treatment sensitivity of alveolar soft part sarcoma: A national multicenter analysis from the French sarcoma group.

European journal of cancer (Oxford, England : 1990)·2026

Related Experiment Video

Updated: Feb 6, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K

[Proton therapy in soft tissue and bone sarcomas].

Juliette Thariat1, Thomas Tessonnier1, Sylvie Bonvalot2

  • 1Centre François-Baclesse, ARCHADE, department of radiation oncology, 3, avenue General-Harris, 14000 Caen, France.

Bulletin Du Cancer
|August 22, 2018
PubMed
Summary

Proton therapy spares healthy tissue, making it a preferred radiation treatment for pediatric sarcomas and skull base tumors. Ongoing trials are evaluating its effectiveness and reduced toxicity in various cancer cases.

Keywords:
HadrontherapyHadronthérapieLevel of evidenceNiveau de preuveProton therapyProtonthérapieSarcomaSarcome

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.1K

Related Experiment Videos

Last Updated: Feb 6, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.2K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.3K
Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies
08:34

Proton Therapy Delivery and Its Clinical Application in Select Solid Tumor Malignancies

Published on: February 6, 2019

21.1K

Area of Science:

  • Oncology
  • Radiation Oncology
  • Pediatric Oncology

Background:

  • Sarcomas are common pediatric tumors.
  • Proton therapy offers superior tissue sparing compared to photon irradiation.
  • It is a validated technique for skull base and spine tumors.

Purpose of the Study:

  • To highlight the benefits of proton therapy in treating sarcomas.
  • To discuss its preferential use in pediatric oncology.
  • To review its efficacy in specific tumor types and potential for toxicity reduction.

Main Methods:

  • Review of proton therapy's application in sarcoma treatment.
  • Discussion of its advantages in pediatric and adult cases.
  • Mention of ongoing prospective and randomized clinical trials.

Main Results:

  • Proton therapy demonstrates significant potential for sparing healthy tissues.
  • It is established for treating specific sarcomas like chondrosarcomas and chordomas.
  • It may reduce acute and late toxicities in adult patients.

Conclusions:

  • Proton therapy is a preferential modality for pediatric sarcomas due to tissue sparing.
  • Its effectiveness in various sarcoma scenarios is under active investigation in clinical trials.
  • Further research aims to confirm its benefits in reducing treatment-related toxicities.